Grants

science_technology_and_other_research_and_development

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mechanism, applications must specifically address at least one of the FY26 ORP CRA Focus Areas.Distinctive Features: ·        The CRA offers two research levels.Research Level 1 (RL1) supports clinical research in the following FY26 ORP focus areas:·        Ligamentous Trauma·        Osseointegration Outcomes·        Return-to-Duty Strategies·        Military Women’s HealthResearch Level 2 (RL2) supports clinical trials in the following FY26 ORP focus areas:·        Ligamentous Trauma·        Limb Stabilization and Protection·        Return-to-Duty Strategies

2026-11-18

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Orthopaedic, Clinical Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mechanism, applications must specifically address at least one of the FY26 ORP CRA Focus Areas.Distinctive Features: The CRA offers two research levels.Research Level 1 (RL1) supports clinical research in the following FY26 ORP focus areas: Ligamentous Trauma Osseointegration Outcomes Return-to-Duty Strategies Military Women s HealthResearch Level 2 (RL2) supports clinical trials in the following FY26 ORP focus areas: Ligamentous Trauma Limb Stabilization and Protection Return-to-Duty Strategies

2026-11-18

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Ovarian Cancer, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

2026-10-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Ovarian Cancer, Clinical Trial Award

science_technology_and_other_research_and_development

Defense Health Agency Contracting Activity - DHACA

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

2026-10-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Focused Pilot Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Focused Pilot Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Idea Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism supports innovative ideas with the potential to yield impactful data and new avenues of investigation. All applications must address at least one of the FY26 PCARP Focus Areas. Distinctive Features: <ul> <li>This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.</li> <li>Partnering Principal Investigator (PI) Option for Early-Career Investigator: This funding mechanism offers a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research. For this option, only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.</li> </ul>

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Idea Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism supports innovative ideas with the potential to yield impactful data and new avenues of investigation. All applications must address at least one of the FY26 PCARP Focus Areas. Distinctive Features: This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Partnering Principal Investigator (PI) Option for Early-Career Investigator: This funding mechanism offers a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research. For this option, only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. ·        This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. ·        The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson s, Early Investigator Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Parkinson s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features: The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience. Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required. Funding Level 2: Mentor not required. Preliminary data are required. Clinical trials are not allowed.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson s, Investigator-Initiated Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Parkinson s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson s disease research. Research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features: Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs. Preliminary data are required. Clinical trials are allowed.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson’s, Early Investigator Research Award

Dept. of the Army -- USAMRAA

Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features:·        The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.·        Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required.·        Funding Level 2: Mentor not required. Preliminary data are required.·        Clinical trials are not allowed.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson’s, Investigator-Initiated Research Award

Dept. of the Army -- USAMRAA

Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features:·        Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs.·        Preliminary data are required.·        Clinical trials are allowed.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson’s, Early Investigator Research Award

Defense Health Agency Contracting Activity - DHACA

DoW Parkinson’s, Early Investigator Research Award

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Parkinson’s, Investigator-Initiated Research Award

Defense Health Agency Contracting Activity - DHACA

DoW Parkinson’s, Investigator-Initiated Research Award

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Cancer, Clinical Trial Award

Dept. of the Army -- USAMRAA

DoW Peer Reviewed Cancer, Clinical Trial Award

general

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Cancer, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Cancer, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features: Applications to this award mechanism must include a clinical trial. Projects can range from phase 0 to phase III. If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. Applications are required to include patient advocates. Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Cancer, Idea Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public. Distinctive Features: The proposed project should demonstrate creative thinking and innovation.• Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award.• Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale.• New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Cancer, Idea Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public.Distinctive Features: The proposed project should demonstrate creative thinking and innovation. Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award. Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale. New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Medical, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.Supports three funding levels, each offered with and without a Planning Phase:Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $94.5M to fund approximately 9 Clinical Trial Award applications with total cost caps of $800,000 for the planning phase of a Clinical Trial with Planning Phase, $6M for Funding Level 1, $10M for Funding Level 2, and $20M for Funding Level 3 per award. The maximum period of performance is 4 years for the clinical trial, and 12 months for the planning phase. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

2026-09-22

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Medical, Clinical Trial Award

science_technology_and_other_research_and_development

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals. Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date. Supports three funding levels, each offered with and without a Planning Phase: Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants. Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants. Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $94.5M to fund approximately 9 Clinical Trial Award applications with total cost caps of $800,000 for the planning phase of a Clinical Trial with Planning Phase, $6M for Funding Level 1, $10M for Funding Level 2, and $20M for Funding Level 3 per award. The maximum period of performance is 4 years for the clinical trial, and 12 months for the planning phase. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

2026-09-22

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Peer Reviewed Medical, Discovery Award